Express Scripts (ESRX) CMO Issues Blog on CAR-Ts and Gene Therapies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
Juno Therapeutics (JUNO) Prices 6.1M Share Common Offering at $41/Sh
September 22, 2017 5:37 AM EDTJuno Therapeutics, Inc. (NASDAQ: JUNO) today announced the pricing of its follow-on public offering of 6,100,000 shares of its common stock at a price to the public of $41.00 per share. In addition, Juno has granted the underwriters a 30-day option to purchase up to an additional 915,000 shares of common stock. Juno intends to use the net proceeds of the offering for general corporate purposes and working capital.
The offering is expected to close on September 26, 2017, subject to customary closing conditions. Concurrent with the completion of the... More
